New insights on TNF blockers alone for early arthritis

NCT ID NCT02927535

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study followed 813 people with early rheumatoid arthritis in France to see how often doctors prescribe TNF blockers alone (without other arthritis drugs) and how well they work. Researchers tracked symptoms, joint damage, and how long patients stayed on treatment over 5 years. The goal is to learn which patients might benefit most from this approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TNF blockers (a type of drug that blocks inflammation)
What this could lead to: If successful, this study could help doctors better understand when to use TNF blockers alone for early rheumatoid arthritis, potentially improving treatment decisions.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient differences and real-world factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

CHU de Nîmes

Nîmes, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.